What is the "Plant Network Optimization plan" and what is its expected financial impact?

The Plant Network Optimization plan is a strategic initiative by Boston Scientific to simplify its manufacturing operations by transferring production lines and closing certain facilities. The company expects this plan to improve gross profit margins and anticipates annual pre-tax manufacturing cost reductions of approximately $65 million to $80 million by 2012. The total estimated pre-tax charges associated with this plan are between $135 million and $150 million.

What is the reason for the large goodwill impairment charge?

Boston Scientific recorded an estimated $2.7 billion non-cash goodwill impairment charge in the fourth quarter of 2008. This charge is primarily related to the 2006 acquisition of Guidant. The impairment was triggered by a decline in the company's stock price and market capitalization, changes in demand within the CRM (Cardiovascular Rhythm Management) market relative to original acquisition assumptions, and the impact of recent equity and credit market disruptions on the weighted average cost of capital.

Will the goodwill impairment charge affect Boston Scientific's debt obligations?

No, the company stated that this significant $2.7 billion non-cash goodwill impairment charge will not affect the debt covenants under its existing term loan and revolving credit facility agreements.

When can investors expect to see the full financial results and finalized impairment figures?

The press release announcing the fourth quarter and full year 2008 results was issued on January 28, 2009. The company also indicated that it intends to finalize the exact amount of the goodwill impairment charge during the first quarter of 2009.

BSX 8-K: Earnings & Results & Financial Events

Summary

Boston Scientific Corporation (BSX) filed an 8-K on January 28, 2009, reporting financial results for the fourth quarter and full year of 2008, and providing guidance for the first quarter of 2009. The filing also announced significant strategic actions, including a 'Plant Network Optimization plan' aimed at streamlining manufacturing and improving gross profit margins, and a substantial goodwill impairment charge related to the Guidant acquisition. These disclosures are crucial for investors seeking to understand the company's current financial health and future strategic direction. The optimization plan involves transferring production lines and closing facilities, with estimated annual pre-tax manufacturing cost reductions of $65 million to $80 million expected by 2012. This is in addition to previously announced cost-saving measures. Furthermore, BSX recorded a significant non-cash goodwill impairment charge of an estimated $2.7 billion, primarily stemming from the 2006 Guidant acquisition, due to market conditions and a decline in stock price. This impairment, while substantial, is not expected to impact the company's debt covenants.

Key Highlights

1Boston Scientific announced a 'Plant Network Optimization plan' to consolidate manufacturing facilities, aiming for annual pre-tax cost reductions of $65-$80 million by 2012.
2The company estimates total pre-tax charges of $135-$150 million related to the optimization plan, with $120-$130 million involving future cash outlays.
3A significant non-cash goodwill impairment charge of approximately $2.7 billion was recorded for the fourth quarter of 2008, linked to the 2006 Guidant acquisition.
4The goodwill impairment was driven by changes in the CRM market, a decline in stock price, and market volatility impacting the cost of capital.
5The non-cash impairment charge is not expected to affect BSX's existing debt covenants.
6BSX released its fourth quarter and full-year 2008 financial results and provided guidance for the first quarter of 2009.
7The company intends to finalize the goodwill impairment charge amount in the first quarter of 2009.

BOSTON SCIENTIFIC CORP 8-K Report, Financial Results (Jan 29, 2009)

Summary

Key Highlights

Frequently Asked Questions